Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.
EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment
EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma
EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody
EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies
EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies
EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma
EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma
EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma
EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma
EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
EP: 11.Complying with REMS Training and Documentation Requirements
EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM
EP: 13.Unmet Needs in Multiple Myeloma Care
EP: 14.Treatment Sequencing and Combination Therapies for MM
EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma
Now Viewing
EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care
EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics
EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting
EP: 21.Team Approach to Meeting REMS Program Requirements
EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies
EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma
Related Videos
Related Content
